横纹肌溶解症常见并发症及治疗进展

doi:10.11958/20221284

天津医药 ›› 2023, Vol. 51 ›› Issue (3): 329-332.doi: 10.11958/20221284

横纹肌溶解症常见并发症及治疗进展

靳衡¹(), 刘起辉¹, 孙可可¹, 宋洁², 吕琪³, 张艳^△()

1 天津医科大学总医院急诊医学科（邮编300052）
2 中国人民武装警察部队特色医学中心肾病科
3 天津大学应急医学研究院

收稿日期:2022-08-16 修回日期:2022-10-10 出版日期:2023-03-15 发布日期:2023-03-02
通讯作者: 张艳 E-mail:hengjin@tmu.edu.cn;yan-zhang@tmu.edu.cn
作者简介:靳衡（1981），男，副主任医师，主要从事急性肾损伤的诊疗与发病机制方面研究。E-mail：hengjin@tmu.edu.cn
基金资助:
国家自然科学基金面上项目(82072222);国家重点研发计划(2021YFC3002202)

Advances in complications and management of rhabdomyolysis

JIN Heng¹(), LIU Qihui¹, SUN Keke¹, SONG Jie², LYU Qi³, ZHANG Yan^△()

1 Department of Emergency Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
2 Department of Nephrology, Characteristic Medical Center of the Chinese People’s Armed Police Forces
3 Institute of Disaster and Emergency Medicine, Tianjin University

Received:2022-08-16 Revised:2022-10-10 Published:2023-03-15 Online:2023-03-02
Contact: ZHANG Yan E-mail:hengjin@tmu.edu.cn;yan-zhang@tmu.edu.cn

靳衡, 刘起辉, 孙可可, 宋洁, 吕琪, 张艳. 横纹肌溶解症常见并发症及治疗进展[J]. 天津医药, 2023, 51(3): 329-332.

JIN Heng, LIU Qihui, SUN Keke, SONG Jie, LYU Qi, ZHANG Yan. Advances in complications and management of rhabdomyolysis[J]. Tianjin Medical Journal, 2023, 51(3): 329-332.

摘要/Abstract

摘要：

横纹肌溶解症是一种由多种因素引起肌细胞破裂，细胞内容物释放入血而造成组织和器官损伤的综合征。最常见并发症为急性肾损伤，其他并发症有肝损伤、筋膜室综合征、电解质平衡紊乱以及弥散性血管内凝血等。目前常用治疗方法是液体复苏和碱化尿液，出现急性肾衰竭、高钾血症和代谢性酸中毒时，可采取血液透析治疗。新的治疗方面包括生物制剂和干细胞治疗，但多处于研究阶段，最终的临床疗效有待观察。因此明确横纹肌溶解症并发症机制及制定有效治疗方案可能是未来亟待解决的问题。就横纹肌溶解症相关常见并发症及治疗进展进行综述。

关键词: 横纹肌溶解, 急性肾损伤, 挤压综合征, 弥散性血管内凝血, 肌红蛋白

Abstract:

Rhabdomyolysis is a syndrome, in which muscle cell rupture and its contents are released into blood by a variety of factors, causing tissue and organ damage. The most common complication is acute kidney injury, and other complications include liver injury, compartment syndrome, electrolyte imbalance and disseminated intravascular coagulation. Currently, the general treatments are fluid resuscitation and alkalization of urine. Hemodialysis can be used in the presence of acute renal failure, hyperkalemia and metabolic acidosis. New therapeutic strategies include biological agents and stem cell therapy, but most of them are based on the basic research, and the final clinical efficacy remains to be seen. Therefore, clarifying the pathogenesis of its complications and formulating effective treatment plans may be urgent problems to be solved in the future. This article reviews the latest advances in complications and treatment strategies of rhabdomyolysis.

Key words: rhabdomyolysis, acute kidney injury, crush syndrome, disseminated intravascular coagulation, myoglobin

中图分类号:

R685.5

参考文献 45

[1]	ZUTT R, VAN DER KOOI A J, LINTHORST G E, et al. Rhabdomyolysis:review of the literature[J]. Neuromuscul Disord, 2014, 24(8):651-659. doi:10.1016/j.nmd.2014.05.005.
[2]	CABRAL B, EDDING S N, PORTOCARRERO J P, et al. Rhabdomyolysis[J]. Dis Mon, 2020, 66(8):101015. doi:10.1016/j.disamonth.2020.101015.
[3]	KODADEK L, CARMICHAEL Ⅱ S P, SESHADRI A, et al. Rhabdomyolysis:An American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document[J]. Trauma Surg Acute Care Open, 2022, 7(1):e000836. doi:10.1136/tsaco-2021-000836.
[4]	DANTAS G, DE ALKMIM MOREIRA NUNES R, CASIMIRO-LOPES G, et al. Analysis of physiological markers and risk factors for the development of rhabdomyolysis in military personnel:A systematic review[J]. Rev Environ Health, 2022. doi:10.1515/reveh-2022-0038.[Online ahead of print].
[5]	CAI Y, HUANG C, ZHOU M, et al. Role of curcumin in the treatment of acute kidney injury:research challenges and opportunities[J]. Phytomedicine, 2022, 104:154306. doi:10.1016/j.phymed.2022.154306.
[6]	ZHANG J, WANG B, YUAN S, et al. The role of ferroptosis in acute kidney injury[J]. Front Mol Biosci, 2022, 9:951275. doi:10.3389/fmolb.2022.951275.
[7]	CHOU Y T, KAN W C, SHIAO C C. Acute kidney injury and gut dysbiosis:A narrative review focus on pathophysiology and treatment[J]. Int J Mol Sci, 2022, 23(7):3658. doi:10.3390/ijms23073658.
[8]	LIU Y, LI M, TEH L, et al. Emodin-mediated treatment of acute kidney injury[J]. Evid Based Complement Alternat Med, 2022, 2022:5699615. doi:10.1155/2022/5699615.
[9]	JIN H, LIN X, LIU Z, et al. Remote ischemic postconditioning protects against crush-induced acute kidney injury via down-regulation of apoptosis and senescence[J]. Eur J Trauma Emerg Surg, 2022, 48(6):4585-4593. doi:10.1007/s00068-022-01910-5.
[10]	LIN X, JIN H, CHAI Y, et al. Cellular senescence and acute kidney injury[J]. Pediatr Nephrol, 2022, 37(12):3009-3018. doi:10.1007/s00467-022-05532-2.
[11]	BOSS K, KRIBBEN A. Treatment and progression management of acute kidney injury[J]. Dtsch Med Wochenschr, 2022, 147(5):246-252. doi:10.1055/a-1557-6909.
[12]	PLOS ONE Staff. Correction:Penehyclidine hydrochloride pretreatment ameliorates rhabdomyolysis-induced AKI by activating the Nrf2/HO-1 pathway and allevi-ating endoplasmic reticulum stress in rats[J]. PLoS One, 2016, 11(4):e0154138. doi:10.1371/journal.pone.0154138.
[13]	BOUDHABHAY I, POILLERAT V, GRUNENWALD A, et al. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis[J]. Kidney Int, 2021, 99(3):581-597. doi:10.1016/j.kint.2020.09.033.
[14]	MARD S A, HOSEINYNEJAD K, NEJADDEHBASHI F. Gallic acid improves therapeutic effects of mesenchymal stem cells derived from adipose tissue in acute renal injury following rhabdomyolysis induced by glycerol[J]. Inflammation, 2022. doi:10.1007/s10753-022-01691-4. [Online ahead of print].
[15]	AKMAL M, MASSRY S G. Reversible hepatic dysfunction associated with rhabdomyolysis[J]. Am J Nephrol, 1990, 10(1):49-52. doi:10.1159/000168053.
[16]	MELILA M, RAJARAM R, GANESHKUMAR A, et al. Assessment of renal and hepatic dysfunction by co-exposure to toxic metals(Cd,Pb)and fluoride in people living nearby an industrial zone[J]. J Trace Elem Med Biol, 2022, 69:126890. doi:10.1016/j.jtemb.2021.126890.
[17]	SHARMA N, GAIKWAD A B. Ameliorative effect of AT2R and ACE2 activation on ischemic renal injury associated cardiac and hepatic dysfunction[J]. Environ Toxicol Pharmacol, 2020, 80:103501. doi:10.1016/j.etap.2020.103501.
[18]	MA X, XU S, LI J, et al. Selenomethionine protected BMECs from inflammatory injury and oxidative damage induced by Klebsiella pneumoniae by inhibiting the NF-κB and activating the Nrf2 signaling pathway[J]. Int Immunopharmacol, 2022, 110:109027. doi:10.1016/j.intimp.2022.109027.
[19]	LARSEN R, GOUVEIA Z, SOARES M P, et al. Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases[J]. Front Pharmacol, 2012, 3:77. doi:10.3389/fphar.2012.00077.
[20]	PAPAGEORGIOU C, JOURDI G, ADJAMBRI E, et al. Disseminated intravascular coagulation:An update on pathogenesis,diagnosis,and therapeutic strategies[J]. Clin Appl Thromb Hemost, 2018, 24(9_suppl):8S-28 S. doi:10.1177/1076029618806424.
[21]	BAATARJAV C, KOMADA T, KARASAWA T, et al. dsDNA-induced AIM2 pyroptosis halts aberrant inflammation during rhabdomyolysis-induced acute kidney injury[J]. Cell Death Differ, 2022. doi:10.1038/s41418-022-01033-9. [Online ahead of print].
[22]	LELONGE Y, GAVID M, VIEVILLE M, et al. Tension pneumoperitoneum and acute abdominal compartment syndrome during panendoscopy[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2022: S1879- 7296(22)00067-9. doi:10.1016/j.anorl.2022.06.006.
[23]	RITCHIE E D, VOGELS S, VAN DONGEN T, et al. Systematic review of innovative diagnostic tests for chronic exertional compartment syndrome[J]. Int J Sports Med, 2022. doi:10.1055/a-1866-5957. [Online ahead of print].
[24]	CHEN X, WANG X, HONORE P M, et al. Renal failure in critically ill patients, beware of applying (central venous)pressure on the kidney[J]. Ann Intensive Care, 2018, 8(1):91. doi:10.1186/s13613-018-0439-x.
[25]	KIM H W, KIM S, OHN J H, et al. Role of bicarbonate and volume therapy in the prevention of acute kidney injury in rhabdomyolysis:A retrospective propensity score-matched cohort study[J]. Kidney Res Clin Pract, 2022, 41(3):310-321. doi:10.23876/j.krcp.21.093.
[26]	PEZZI M, GIGLIO A M, SCOZZAFAVA A, et al. Early intensive treatment to prevent kidney failure in post-traumatic rhabdomyolysis:Case report[J]. SAGE Open Med Case Rep, 2019, 7:2050313X19839529. doi:10.1177/2050313X19839529.
[27]	BROWN C V, RHEE P, CHAN L, et al. Preventing renal failure in patients with rhabdomyolysis:do bicarbonate and mannitol make a difference?[J]. J Trauma, 2004, 56(6):1191-1196. doi:10.1097/01.ta.0000130761.78627.10.
[28]	ZHENG T, LIU L, LIU J, et al. Rhabdomyolysis happened after the start of dabigatran etexilate treatment:A case report[J]. J Musculoskelet Neuronal Interact, 2022, 22(2):296-300.
[29]	陈艾萍, 王建文, 伍宏. 不同血液净化模式治疗横纹肌溶解症的疗效比较[J]. 中华卫生应急电子杂志, 2020, 6(6):332-336.
	CHEN A P, WANG J W, WU H. Comparison of different blood purification modes in rhabdomyolysis[J]. Chinese Journal Hygiene Rescue, 2020, 6(6):332-336. doi:10.3877/cma.j.issn.2095-9133.2020.06.002.
[30]	GUPTA A, THORSON P, PENMATSA K R, et al. Rhabdomyolysis:Revisited[J]. Ulster Med J, 2021, 90(2):61-69.
[31]	YANG X Y, SONG J, HOU S K, et al. Ulinastatin ameliorates acute kidney injury induced by crush syndrome inflammation by modulating Th17/Treg cells[J]. Int Immunopharmacol, 2020, 81:106265. doi:10.1016/j.intimp.2020.106265.
[32]	WANG J, XU G, JIN H, et al. Ulinastatin alleviates rhabdomyolysis-induced acute kidney injury by suppressing inflammation and apoptosis via inhibiting TLR4/NF-κB signaling pathway[J]. Inflammation, 2022, 45(5):2052-2065. doi:10.1007/s10753-022-01675-4.
[33]	HIGGINS S P, TANG Y, HIGGINS C E, et al. TGF-β1/p53 signaling in renal fibrogenesis[J]. Cell Signal, 2018, 43:1-10. doi:10.1016/j.cellsig.2017.11.005.
[34]	YUQIANG C, LISHA Z, JIEJUN W, et al. Pifithrin-α ameliorates glycerol induced rhabdomyolysis and acute kidney injury by reducing p53 activation[J]. Ren Fail, 2022, 44(1):473-481. doi:10.1080/0886022X.2022.2048857.
[35]	GOIS P, CANALE D, VOLPINI R A, et al. Allopurinol attenuates rhabdomyolysis-associated acute kidney injury:Renal and muscular protection[J]. Free Radic Biol Med, 2016, 101:176-189. doi:10.1016/j.freeradbiomed.2016.10.012.
[36]	BOLISETTY S, ZARJOU A, AGARWAL A. Heme oxygenase 1 as a therapeutic target in acute kidney injury[J]. Am J Kidney Dis, 2017, 69(4):531-545. doi:10.1053/j.ajkd.2016.10.037.
[37]	OHTANI S, SHIMIZU H, YAMAOKA M, et al. Protective effect of tin chloride on rhabdomyolysis-induced acute kidney injury in rats[J]. PLoS One, 2022, 17(3):e0265512. doi:10.1371/journal.pone.0265512.
[38]	WANG J, CHEN Z, HOU S, et al. TAK-242 attenuates crush injury induced acute kidney injury through inhibiting TLR4/NF-κB signaling pathways in rats[J]. Prehosp Disaster Med, 2020, 35(6):619-628. doi:10.1017/S1049023X20001132.
[39]	CREAGH-BROWN B C, QUINLAN G J, EVANS T W, et al. The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction:an important therapeutic target?[J]. Intensive Care Med, 2010, 36(10):1644-1656. doi:10.1007/s00134-010-1952-z.
[40]	GUARNERI F, CUSTURONE P, PAPAIANNI V, et al. Involvement of RAGE and oxidative stress in inflammatory and infectious skin diseases[J]. Antioxidants (Basel), 2021, 10(1):82. doi:10.3390/antiox10010082.
[41]	MATSUMOTO H, MATSUMOTO N, SHIMAZAKI J, et al. Therapeutic effectiveness of anti-rage antibody administration in a rat model of crush injury[J]. Sci Rep, 2017, 7(1):12255. doi:10.1038/s41598-017-12065-4.
[42]	VANPATTEN S, AL-ABED Y. High mobility group box-1(HMGb1):Current wisdom and advancement as a potential drug target[J]. J Med Chem, 2018, 61(12):5093-5107. doi:10.1021/acs.jmedchem.7b01136.
[43]	ZHANG B F, WANG P F, CONG Y X, et al. Anti-high mobility group box-1(HMGB1)antibody attenuates kidney damage following experimental crush injury and the possible role of the tumor necrosis factor-α and c-Jun N-terminal kinase pathway[J]. J Orthop Surg Res, 2017, 12(1): 110. doi:10.1186/s13018-017-0614-z.
[44]	DUFFY M M, GRIFFIN M D. Back from the brink:a mesenchymal stem cell infusion rescues kidney function in acute experimental rhabdomyolysis[J]. Stem Cell Res Ther, 2014, 5(5):109. doi:10.1186/scrt497.
[45]	WANG S, ZHANG C, LI J, et al. Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization[J]. Cell Death Dis, 2017, 8(4):e2725. doi:10.1038/cddis.2017.104.

横纹肌溶解症常见并发症及治疗进展

Advances in complications and management of rhabdomyolysis

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	樊汇, 马宇, 李曦铭. 预防对比剂相关性急性肾损伤的研究进展[J]. 天津医药, 2024, 52(3): 327-330.
[2]	耿永芝, 杨利, 李国伟, 张金涛, 程晓磊, 檀立端. 川陈皮素对急性肾损伤大鼠的改善作用及机制研究[J]. 天津医药, 2023, 51(5): 498-503.
[3]	刘竹枫, 王文红, 范树颖, 刘艳, 刘涛, 王欣, 吴瑕. Klotho蛋白对肾缺血再灌注大鼠急性肾损伤及纤维化的保护作用[J]. 天津医药, 2023, 51(4): 371-375.
[4]	管光辉, 浦秦华, 钱何布. 脓毒症并发急性肾损伤患者血清MMP-13、VASH-1水平与预后相关性[J]. 天津医药, 2023, 51(12): 1360-1264.
[5]	王建林, 王琰华, 史磊. 急性心肌梗死患者LGE-CMR评价结果及其与血清心肌标志物的关系[J]. 天津医药, 2022, 50(4): 393-938.
[6]	张艳, 靳衡, 曹超, 寿松涛△. uNGAL联合尿NAG对危重症患者急性肾损伤病情及预后的评估价值#br#[J]. 天津医药, 2021, 49(5): 495-498.
[7]	安丽平, 王伟, 杨洪霞, 安然, 于琨, 吴广礼, 李云峰. 山莨菪碱对横纹肌溶解致急性肾损伤大鼠保护作用的研究#br#[J]. 天津医药, 2021, 49(4): 364-370.
[8]	陈德珠, 曾繁琨, 钟建, 张力. 危重症脓毒症并发急性肾损伤进展至慢性肾脏病危险因素分析 #br#[J]. 天津医药, 2021, 49(2): 165-168.
[9]	温小龙, 邢柏△. 万古霉素单药与联合β-内酰胺类药物对脓毒症患者急性肾损伤发生和预后的影响#br#[J]. 天津医药, 2021, 49(1): 36-40.
[10]	曹臻, 倪春华△. 血清心型脂肪酸结合蛋白对脓毒症患者并发急性肾损伤的预测价值[J]. 天津医药, 2020, 48(11): 1091-1095.
[11]	贺倩 , 李蕃健 , 赵子龙 , 马菲 . 颅内压监测对创伤性脑损伤患者短期预后及急性肾损伤发生的影响[J]. 天津医药, 2019, 47(5): 493-496.
[12]	程巧林，周艳玲，王丹虹，林则彬，刘玉玲. 尿白细胞介素18和血清高迁移率族蛋白1对新生儿窒息后急性肾损伤的诊断价值[J]. 天津医药, 2019, 47(5): 513-516.
[13]	李文宇 , 依力哈木江·艾沙 , 阿达莱提·阿卜力孜 , 沙德尔丁·斯拉吉 , 杜纪兵 . RAAS抑制剂在对比剂致维吾尔族患者性肾损伤中的作用[J]. 天津医药, 2019, 47(5): 517-520.
[14]	杨蕊, 许华, 王兵, 王勇强. PI3K/AKT信号通路在大鼠腹腔感染性脓毒症急性肾损伤中的作用[J]. 天津医药, 2018, 46(6): 581-584.
[15]	张莹1,张碧丽2△，王丹1. 尿NGAL在新生儿窒息后急性肾损伤诊治中的临床价值[J]. 天津医药, 2018, 46(11): 1226-1229.